FindTrial
Sign In

Cisplatin for injection

DRUG6 trials

Sponsors

EpicentRx, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Allist Pharmaceuticals, Inc., Qilu Pharmaceutical Co., Ltd., Shanghai Guangsheng Biopharmaceutical Co., Ltd

Conditions

Biliary Tract Cancers (BTC)CLDN18.2-positive Advanced Biliary Tract CancerEGFRLocally Advanced Unresectable Esophageal Squamous CarcinomaNSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Patients With Brain MetastasisOral Mucositis

Phase 1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
Not yet recruitingNCT06136988
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Locally Advanced Unresectable Esophageal Squamous Carcinoma
Start: 2023-12-31End: 2028-04-30Target: 129Updated: 2023-11-18

Phase 2

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
CompletedNCT03515538
EpicentRx, Inc.Oral Mucositis
Start: 2018-07-12End: 2020-10-08Updated: 2024-11-04
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
Not yet recruitingNCT07151872
Qilu Pharmaceutical Co., Ltd.CLDN18.2-positive Advanced Biliary Tract Cancer
Start: 2025-09-30End: 2026-10-31Target: 120Updated: 2025-09-03
Cosiporfin Sodium for Injection Photodynamic Therapy
RecruitingNCT07398339
Shanghai Guangsheng Biopharmaceutical Co., LtdBiliary Tract Cancers (BTC)
Start: 2026-03-31End: 2028-03-31Target: 30Updated: 2026-02-09

Phase 3

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
RecruitingNCT06956001
Allist Pharmaceuticals, Inc.EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Start: 2024-11-19End: 2028-07-01Target: 300Updated: 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
RecruitingNCT06970639
Allist Pharmaceuticals, Inc.NSCLC Patients With Brain Metastasis
Start: 2024-09-26End: 2029-09-01Target: 380Updated: 2026-02-12

Related Papers

RRx-001 potentially reduces financial toxicity for patients and caregivers in head and neck cancer.
JCO Oncology Practice2023-10-26
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
2023-03-1528 citations
Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in patients with head and neck cancer treated with chemoradiation (PREVLAR).
Journal of Clinical Oncology2022-06-013 citations
Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).
Journal of Clinical Oncology2020-05-201 citations